Activation of the TBK1-IFN pathway by MEDI2228 enhances CD38 expression in multiple myeloma cells, thereby augmenting the anti-tumor effects of CD38-targeting antibody-drug conjugates (87). Here, CD38 is linked to plasma cell myeloma.